Sign up


Match Document Document Title
8703128 Methods of modulating TGFβ signaling  
The present invention provides methods of identifying the presence of or quantifying the amount of one or more of T helper (Th) cells and iTreg cells present in a sample by identifying the presence...
8703731 Sphingosine-bound siRNA  
The invention relates to novel oligomer analogues and their use in oligonucleotide-based therapies. More specifically, the invention concerns oligonucleotides carrying lipid molecules and their use...
8703735 Antisense antiviral compounds and methods for treating a filovirus infection  
The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family,...
8703930 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes  
The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation....
8703732 Composition for enhancing TRAIL sensitivity comprising inhibitors for expression or activity of TIP41 as a target gene of TRAIL sensitizer  
The present invention relates to a pharmaceutical composition, including inhibitors for expression or activity of TIP41 protein, for prevention and treatment of cancer. When the liver cancer cell...
8703730 Complement antagonists and uses thereof  
Disclosed are antagonists designed to inhibit or block expression of a mammalian complement such as complement component 6 (C6). The invention has a wide range of uses including use in the...
8703728 Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini  
The present invention relates to bicyclic nucleosides and oligomeric compounds comprising at least one such nucleoside. These oligomeric compounds typically have enhanced binding affinity and...
8703729 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene  
A mixture comprising at least one inhibitor or suppressor of the expression of a gene and at least one molecule binding to an expression product of said gene.
8697666 Anti-cancer oligodeoxynucleotides  
It is disclosed herein that suppressive OD Ns are of use for preventing or delaying the formation of a tumor, reducing the risk of developing a tumor, treating a tumor, preventing conversion of a...
8697667 Cyclodextrin-modified polyamines for delivery of therapeutic molecules  
The present invention is directed to drug delivery vehicles comprising one or more cyclodextrin moieties conjugated to a dendritic polyamine for the delivery of small molecule and protein...
8697663 Oligomeric compounds and compositions for use in modulation of small non-coding RNAs  
Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding...
8697628 Methods of using AMPD2 inhibitors for the treatment of fatty liver, obesity and diabetes  
The present invention provides compounds and compositions that modulate adenosine monophosphate deaminase (AMPD) and methods for using the same to treat a clinical condition associated with the...
8697668 Compositions and methods for preventing and treating cancer via modulating UBE1L, ISG215 and/or UBP43  
Compositions and methods of using compositions that induce UBE1L or a ubiquitin-like protein ISG15, or inhibit a deconjugase UBP43 to degrade oncogenic proteins and enhance apoptosis of cancer...
8691967 Multiple promoter expression cassettes for simultaneous delivery of RNAi agents  
The present invention provides multiple-promoter expression cassettes for simultaneous delivery of RNAi, preferably to mammalian cells in vivo.
8691965 Oligonucleotides for modulating target RNA activity  
The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The...
8691785 Compositions and methods for non-parenteral delivery of oligonucleotides  
The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration....
8691971 Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference  
Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular...
8691783 MicroRNA-24  
The present invention relates to a modulator, in particular an inhibitor, of microRNA-24 (miR-24) and to direct and indirect miR-24 targets for use in a method of treatment and/or prevention of...
8689459 Method and apparatus for spray drying and powder produced using said method  
Method for spray drying a high-viscosity fluid product using a spraying device, wherein the method comprises projecting the fluid product out of an outflow opening of the spraying device for...
8691780 Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby  
Methods and compositions for enhancing taxane sensitivity are provided. Aspects of the subject methods include administering to a subject a txr1 pathway modulatory agent in conjunction with a...
8691784 MCP-1 binding nucleic acids  
The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group consisting of Type 1A nucleic acids, type 1B nucleic acids, Type 2 nucleic acids, Type 3...
8685940 Impaired wound healing compositions and treatments  
Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods,...
8685937 Nucleic acid aptamers  
The present invention relates to optimized aptamers and methods of using these aptamers.
8686052 Targeting agent for cancer cell or cancer-associated fibroblast  
Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a...
8680066 Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject  
The invention provides methods for determining whether a subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene comprising contacting isolated fibroblasts from the...
8680067 Targeting microRNAs for the treatment of liver cancer  
Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide...
8679750 Methods and compositions for the treatment of Huntington'S disease  
Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid...
8680065 Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use  
Described herein are oligonucleotides that target the human endogenous retrovirus-9 (ERV-9) long terminal repeat (LTR). The ERV-9 LTR oligonucleotides specifically hybridize with either the coding...
8673873 RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders  
RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA...
8673871 Compounds and methods for modulating expression ApoB  
The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense...
8673874 Methods for treating pancreatic cancer  
The present invention provides a method of treating pancreatic cancer by inhibiting the activity cyclin D1 activity in tumor cells. The invention is based on the finding that cyclin D1 shRNA...
8673872 Method of modulation of expression of epidermal growth factor receptor(EGFR) involving miRNA  
The present invention relates to a method for modulating the expression of epidermal growth factor receptor (EGFR) and its downstream signalling effectors. In particular, the present invention...
8673869 Determinants of sensitivity to chemotherapeutic agents  
The present invention provides methods for determining the level of resistance of a tumor cell to one or more chemotherapeutic agents, comprising measuring the level of expression of a muscle...
8668933 Polyion complex of double-stranded ribonucleic acid  
Provided are a delivery system that is useful in delivering a double-stranded ribonucleic acid that functions in gene silencing in glomeruli, particularly in mesangial cells and the like, to the...
8669236 Biotinylated compositions  
Novel biotinylated composition comprising a nucleic acid, e.g. siRNA, that are useful for targeting therapeutic and imaging agents to sites of infection and tumors are disclosed.
8669238 Use of Kif13A and AP-1 inhibitors for inhibiting melanogenesis  
The present invention relates to novel pharmaceutical or cosmetic compositions comprising at least one inhibitor of a sub-unit of AP-1 adaptor complex, of a kinesin interacting with AP-1, in...
8664193 Compositions and methods for inhibiting expression of factor VII gene  
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
8664188 siRNA compositions and methods for potently inhibiting viral infection  
No antiviral regimen has been consistently successful in treating H5N1 virus infection. We demonstrate that a group of highly effective siRNAs targeting different H5N1 viral genes shares a unique...
8664192 Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer  
Methods of reducing spontaneous mutation rate of a cell in a subject in need thereof by reducing endogenous levels of miR-155 are described.
8664190 Methods for treating hypercholesterolemia  
Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating,...
8658613 Methods and compositions of nucleic acid ligands for detection of clinical analytes related to human health  
Specific DNA sequences for binding various clinically relevant analytes from the human body are described. Each of these sequences or their linear, two- and three-dimensional linked sequences can...
8658608 Modified triple-helix forming oligonucleotides for targeted mutagenesis  
High affinity, chemically modified triplex-forming oligonucleotides (TFOs) and methods for use thereof are disclosed. TFOs are defined as triplex-forming oligonucleotides which bind as third...
8658615 Prohibitin as target for cancer therapy  
The present invention relates to pharmaceutical compositions comprising inhibitors of Prohibitin (PHB) for the prevention or/and treatment of hyperproliferative disorders.
8658614 Aptamer-containing compositions and methods for targeting E-selectin  
An isolated nucleic acid molecule that selectively binds to an E-selectin protein comprises a contiguous 29-30 nucleotide sequence that includes at least one monothiophosphate or a dithiophosphate...
8658211 Polyconjugates for in vivo delivery of polynucleotides  
The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates...
8653047 Modulation of angiopoietin-like 3 expression  
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for...
8652526 Drug carrier and drug carrier kit for inhibiting fibrosis  
An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a...
8653044 Sex-specific regulation of aging and apoptosis  
The invention provides anti-apoptotic agents and therapies and uses thereof. Specifically, the anti-apoptotic agents and therapies involve human Xist gene, Xist RNA, Xist gene product, and...
8648052 Prevention of chlamydia infection using SIRNA  
The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections. The methods and compositions inhibit the entry of Chlamydia into a host cell...
8648053 Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome  
The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a...